Pfizer的Hospira工廠生產不合規問題存在已久, 只是產業中沒有其他人可以生產了嗎? 不知什麼原因 40mg capaxone仿製藥會委託 Hospira工廠生產?查看全文
鹰眼形态忍者狙击手2017-10-04 22:26
$Momenta Pharmaceuticals, Inc.(MNTA)$ 卖出体系之跌破前一根K之重要性:不遵守就是如此的惨不忍睹查看全文
淘沙见金2017-10-04 20:12
$Mylan(MYL)$ The FDA approves Mylan N.V.'s (NASDAQ:MYL) generic version of Teva Pharmaceutical Industries' (NYSE:TEVA) top seller Copaxone (glatiramer acetate injection) 40 mg/mL for the treatment of relapsing forms of multiple sclerosis. Shipments will begin immediat...查看全文
鹰眼形态忍者狙击手2017-09-30 09:56
$Momenta Pharmaceuticals, Inc.(MNTA)$ 连续5根阳线很少,大概率走出一根阴线,主力会永远的利用散户的贪婪本性赚钱查看全文
鹰眼形态忍者狙击手2017-09-28 10:41
$Momenta Pharmaceuticals, Inc.(MNTA)$ 业绩不好,但是未来光明,即使高层卖出股票,一样上涨,高层卖出有很多原因,不一定不看好,也可能缺钱急用。查看全文
淘沙见金2017-09-12 02:57
Pfizer's EpiPen manufacturer warned by FDA. The FDA's warning looks to be the culmination of several voluntary recalls Mylan enacted in the spring for EpiPen product coming from St. Louis-based Meridian.除了$Mylan(MYL)$ ,辉瑞的这家药厂坑了不少公司啊,$Achaogen, Inc.(A...查看全文
淘沙见金2017-08-04 03:21
$梯瓦制药(TEVA)$ TEVA的麻烦也许才刚刚开始。Copaxone贡献了将近20%的收益,如果下半年 $Momenta Pharmaceuticals, Inc.(MNTA)$ 和Sandos的Glatopa 40mg上市收益会进一步减小。目前pipeline 没有看到有畅销药的潜力,治疗偏头痛的anti CGRP药物至少还要一年半才能被FDA批准,而且也是个多家竞争的...查看全文
淘沙见金2017-07-06 11:00
说起仿制复合药和生物仿制药,你可能首先想到的是TEVA ($梯瓦制药(TEVA)$ 和Mylan ($Mylan(MYL)$ 。 今天要介绍的这个公司- Momenta Pharmaceuticals ($Momenta Pharmaceuticals, Inc.(MNTA)$ ,比起上述两大巨头可能名气不大,不过潜力倒是不小。
MOMENTA旗下已经上市的产品包括LOVENOX和Cop...查看全文
$摩蒙塔制药(MNTA)$ 15-12G Securities registration termination [Section 12(g)] Accession Number: 0001193125-20-267996 Act: 34 Size: 11 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010061 Size: 14 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010062 Size: 7 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010063 Size: 14 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010064 Size: 24 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010059 Size: 26 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010060 Size: 16 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010056 Size: 48 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010057 Size: 34 KB 网页链接
$摩蒙塔制药(MNTA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010058 Size: 7 KB 网页链接